19 results on '"Haupt, Axel"'
Search Results
2. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
3. LBO-001 Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
4. Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
5. Volenrelaxin (LY3540378) increases Renal Plasma Flow: A Randomized Phase 1 Trial
6. New improved radiometabolite analysis method for [18F]FTHA from human plasma: a test-retest study with postprandial and fasting state.
7. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
8. Once Weekly (QW) Insulin Efsitora alfa (Efsitora) and Daily Degludec (DEG) Achieve Comparable Glycemic Control in 3 Patient Populations Studied During Phase 2: Clinical Insights from CGM Assessments.
9. Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial.
10. Effect of Orforglipron versus Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes.
11. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study.
12. Initiation of Once Weekly (QW) Insulin Efsitora alfa (efsitora) in 3 Patient Populations in Phase 2 Studies Using a One-time Loading Dose (LD) Minimizes Transient Hyperglycemia and is not Associated with Excess Hypoglycemia Risk vs Degludec.
13. Effects of Tirzepatide on Eating Behaviour: A Phase 1 Study in People Living with Obesity.
14. Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study.
15. A Long-Acting Glucose Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss Without Nausea or Vomiting.
16. Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5.
17. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy.
18. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
19. New improved radiometabolite analysis method for [ 18 F]FTHA from human plasma: a test-retest study with postprandial and fasting state.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.